FBI Probes Who Knew What and When In Power Morcellation Imbroglio

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

This article is part of The Cancer Letter's How Medical Devices Do Harm series.

The Federal Bureau of Investigation is reportedly trying to establish whether Johnson & Johnson—one of the largest manufacturers of power morcellators—knew as early as nine years ago that the gynecological device can disseminate uterine cancers.

According to the Wall Street Journal, the FBI’s Newark, N.J. office interviewed three people, including Robert Lamparter, a retired pathologist who alerted Ethicon, a J&J subsidiary, about potential problems with morcellators in 2006.

A full account of Lamparter’s 2006 complaint can be found at the Pittsburgh Business Times, which reported on the whistleblower case in May 2014.

FBI agents also interviewed Amy Reed, the doctor who led the campaign against power morcellation, as well as Sarah Robinson, a physician assistant in Los Altos, Calif., who told the WSJ she sent an FBI agent a list of 386 names of patients and their families who may have been harmed by the device.

It’s not publicly known whether a formal investigation has been launched. The FBI declined to comment, in response to a previous inquiry from The Cancer Letter, on the “existence or nonexistence” of an investigation (The Cancer Letter, April 10).

J&J officials told the WSJ that they were not aware of an FBI investigation. The company pulled its power morcellators from the market in July 2014, after the FDA issued a warning, and after an FDA advisory panel expressed low confidence in power morcellation as a treatment for uterine fibroids (The Cancer Letter, Aug. 1, 2014).

The FBI may be looking into whether J&J had violated federal law by neglecting to report adverse events, Hooman Noorchashm, Reed’s husband, said previously to this reporter (The Cancer Letter, April 10). Noorchashm is a cardiac surgeon at the Thomas Jefferson University Hospital.

Reed and Noorchashm’s interview with The Cancer Letter appeared on the ABC News coverage of the FBI investigation May 27.

YOU MAY BE INTERESTED IN

In his first sit-down interview since beginning his role as FDA commissioner 17 days earlier, Marty Makary, a former Johns Hopkins surgeon and the only Trump pick for HHS whose confirmation received Democratic support, said he would speed up approvals for rare-disease treatments by reducing reliance on animal testing and shifting towards organoids and computational models. 
The American Cancer Society’s recent report on the increasing incidence rates of colorectal cancer in young adults once again rang an alarm bell for adults over 45 to get checked, especially if they are having symptoms. But as an oncologist with more than 40 years of experience, I also believe that this should be a clarion call to scientists and researchers, and for regulators at the FDA.
Matthew Bin Han Ong
Matthew Bin Han Ong

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login